echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Summary of financial statements of global large pharmaceutical enterprises (Q4 2014)

    Summary of financial statements of global large pharmaceutical enterprises (Q4 2014)

    • Last Update: 2015-03-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: global enterprise dynamics March 3, 2015: Johnson & Johnson, an American pharmaceutical company, reported its financial results for the fourth quarter and the whole year of 2014 Johnson & Johnson's fourth quarter revenue was $18.25 billion, down 0.6% from $18.4 billion in the same period last year; its net profit was $2.5 billion, down from $3.5 billion in the same period last year In 2014, global sales reached US $74.3 billion, up 4.2% year on year Pfizer, the pharmaceutical company, reported fourth quarter and full year results for fiscal 2014 Pfizer's fourth quarter revenue was $13.118 billion, down 3% from $13.558 billion in the same period last year; its net profit was $1.228 billion, down 52% from $2.568 billion in the same period last year Throughout fy2014, Pfizer's revenue was $49.605 billion, down 4% from $51.584 billion in fy2013; its net profit was $9.135 billion, down 58% from $22.003 billion in fy2013 Merck & Co, the US pharmaceutical giant, recorded revenue of $10.48 billion in the fourth quarter of 2014, down 7.4% from the same period last year; its net profit was $7.32 billion, far higher than $781 million in the same period last year, as the company sold its personal care business In the fourth quarter, the revenue of Merck's pharmaceutical sales business was US $9.37 billion, down 4% year on year; the revenue of animal health department was US $885 million, up 2% year on year Abbott Laboratories' fourth quarter earnings exceeded expectations The company's fourth quarter net profit increased to $905 million from $589 million a year earlier Revenue increased 5.6% to $5.36 billion, slightly lower than analysts' average expectations, mainly due to the decline in nutrition business revenue Bristol Myers Squibb, the pharmaceutical giant of Bristol Myers, reported revenue exceeding market expectations in the fourth fiscal quarter Despite the company's divestiture of diabetes business last year and the adverse impact of a stronger dollar, the strong sales of key drugs boosted the fourth quarter's revenue growth Squibb's net profit for the whole quarter was 13 million US dollars, compared with 726 million US dollars in the same period of last year Quarterly revenue decreased 4.1% year-on-year to $4.26 billion But excluding the impact of the divestiture of diabetes, global revenue grew 6% year-on-year Eli Lilly reported fourth quarter and full year results for fiscal 2014 Lilly's fourth quarter revenue was $5.12 billion, down 12% from the same period last year; its net profit was $425.5 million, down 41% from $725.5 million in the same period last year In the whole 2014 fiscal year, Lilly pharmaceutical's total revenue was US $19.616 billion, down 15% from US $23.113 billion in 2013; its net profit was US $2.391 billion, down 49% from US $4.685 billion in 2013 Abbvie, the US drug maker, posted a net loss of $810 million in the fourth quarter, up from $1.128 billion a year earlier Revenue increased to $5.42 billion from $5.11 billion a year earlier Biogen IC Inc., a biotech company, reported fourth quarter earnings that beat analysts' estimates Biogen said the company recorded a net surplus of $882.6 million in the fourth quarter, almost double the $457.3 million recorded in the same period last year The company recorded revenue of $2.64 billion in the fourth quarter, compared with $1.97 billion in the same period last year Allergan Inc reported a net surplus of $537.2 million in the fourth quarter, compared with $312.9 million in the same period last year Sales in the fourth quarter were $1.91 billion, compared with $1.68 billion in the same period last year Amgen Inc reported higher than expected fourth quarter profits The world's largest biotechnology company reported a net profit of $1.29 billion, compared with $1.02 billion in the same period last year Revenue rose 6% to $5.33 billion Gilead Sciences Inc had a net surplus of $3.49 billion in the fourth quarter, compared with $791 million a year earlier Revenue increased from $3.12 billion to $7.31 billion According to the financial report released by Novartis, the European pharmaceutical company, Q4's net profit was $1487 million, down 26%; its net sales was $14.633 billion, down 2% For the whole year, Novartis' net profit was US $10.28 billion, up 12%; net sales was US $57.996 billion, up 1% In 2014, Novartis invested a total of US $9.9 billion in R & D, an increase of about 1% over 2013 Most of these investments were used for advanced clinical research of drugs Roche, the world's largest cancer drug company, posted strong results in 2014 Sales increased by 5% year on year, from CHF 46.780 billion in 2013 to CHF 47.462 billion, including CHF 36.696 billion in the pharmaceutical sector and CHF 10.766 billion in the diagnostic sector The core operating profit was chf17.636 billion in 2014 and chf17.904 billion in 2013 Core net profit was CHF 12.533 billion in 2014 and CHF 12.526 billion in 2013 GlaxoSmithKline PLC's fourth quarter net profit fell 58% to £ 1.03 billion Revenue fell 10% to £ 6.19 billion GlaxoSmithKline's 2014 revenue was £ 23 billion, down 3% from the previous year AstraZeneca, a British pharmaceutical company, lost money in the fourth quarter of fiscal year AstraZeneca had a net loss of $321 million in the fourth quarter, compared with a net profit of $1.5 billion in the previous year Revenue for the quarter fell 2% year-on-year to $6.68 billion Sanofi group achieved strong financial performance in 2014, and its progress in the introduction of new drug markets was remarkably stable Group sales increased 4.9% year-on-year to EUR 33.77bn Net profit increased 6.7% year-on-year to EUR 6.847 billion Bayer's sales increased by 5.2% in 2014 to 42.239 billion euros, compared with 40.157 billion euros in 2013; the sales of its healthcare subsidiary reached 19.975 billion euros EBIT increased 11.6% to 5.506 billion euros Net income increased by 7.4% to EUR 3426 million In the fourth quarter of 2014, sales of Bayer Group increased by 11.6% to 11.039 billion euros, compared with 9888 million euros in the fourth quarter of 2013; net income fell to 224 million euros, compared with 455 million euros in the fourth quarter of 2013 Novo Nordisk's 2014 annual report shows that the company continues to grow In 2014, the company's turnover was DKK 88.8 billion, up 6%, EBIT was DKK 34.5 billion, up 10%, and net profit was DKK 26.48 billion, up 5% The company's profit margin was 38.8%, higher than 37.7% in 2013 Novozymes had a pre tax profit of DKK 843 million and a net profit of DKK 603 million in the fourth quarter of 2014, compared with DKK 703 million and DKK 563 million in the same period of 2013 The company outperformed the industry analysis in the quarter When sales of dinovision increased to DKK 31.81 from DKK 2.94 billion last year Koninklijke DSM N.V., a DSM global life science and materials science company, released its 2014 unaudited performance report DSM's sales in 2014 were 9.181 billion euros, up 4% year on year EBITDA amounted to EUR 1.168 billion in 2014 and EUR 1.261 billion in 2013 EBITDA in the fourth quarter of 2014 was EUR 288 million, compared with EUR 297 million in the same period last year.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.